

# Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

NCT05754710

---

**Status** RECRUITING  
**Sponsor** Pfizer  
**Enrollment** 10 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Pediatric subjects aged from 2 years to less than 18 years
- Xeljanz administered according to efficacy/effectiveness on the approved labeling
- Patients who will administer Xeljanz based on the medical judgement of the investigator
- Evidence of a personally signed and dated informed consent document indicating that the subject (and a legally acceptable representative) has been informed of all pertinent aspects of the study

### Exclusion (3)

- Subjects meeting any of the following criteria will not be included in the study:
- \) Subjects who are contraindicated from taking Xeljanz according to approved labeling\\*
- \\*Refer to most recently approved label

## Locations (1 total)

---

Pfizer, Seoul, South Korea